Canaccord analyst Mark Massaro reiterated a Buy rating on Idexx Laboratories (IDXX) and raised his price target to $255 after holding meetings with CFO Brian McKeon and Senior Director of Finance and Head of IR John Ravis. Massaro tells investors in a research note that the meetings reinforced his conviction that Idexx remains an "outstanding" company and, relative to reasonable expectations, sets the stage for another good year for shareholders. He also feels that investor concerns on a combined Zoetis (ZTS)-Abaxis are "overblown," and says Idexx has a realistic chance to exceed its all-time high of $254 per share in the not-too-distant future.

Barclays lowered the firm's price target on Zoetis to $230 from $260 and keeps an Overweight rating on the shares ahead of the Q1 report. The analyst expects the Q1 reports to provide continuing evidence of improvement in generics and biosimilars for the specialty pharmaceuticals group.

Jefferies analyst Glen Santangelo lowered the firm's price target on Zoetis (ZTS) to $200 from $220 and keeps a Hold rating on the shares. Zoetis shares are down year-to-date on several factors, with the two most significant being Librela safety concerns and pending competition launches from Elanco (ELAN), the analyst tells investors in a research note. The firm, however, conducted a survey of 35 veterinarians and says the data looks largely positive for Zoetis. While the competitive landscape around key products bears monitoring, the stock's current valuation discount "seems overly punitive," contends Jefferies. The firm believes this "battered expectation level represents an attractive buying opportunity" ahead of the company's Q1 report. Jefferies notes that 100% of the 35 of vets it surveyed are happy, either very or somewhat, with Librela efficacy while 97% were neutral to happy with the safety profile. Meanwhile, 50% of respondents expect osteoarthritis pain scripts to growth 11%-30% in the next two years, the firm adds.